Craig Julien
Family Medicine · West Point, UTNPI 1245340173
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,638 of the $3,507 with a category attached, or 75.2%. 25 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 35.5% of the total. Reporting peaked in 2023 at $1,244 and has fallen 87.9% since, to $150 in 2024.
Across 159 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- AstraZeneca$370
- Novo Nordisk$279
- Boehringer Ingelheim$260
- Lilly USA, LLC$256
- AbbVie$212
- plus $886 from 19 others
Across 171 payments — averaging $8045.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$338K
- Boehringer Ingelheim$320K
- Amgen$248K
- Novavax Inc$135K
- Orasure Technologies Inc.$90K
- Astrazeneca UK Limited$87K
- plus $158K from 5 others
What the payments were for
- Travel & lodging$86925%
- Food & beverage$2,63875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,244 |
| AstraZeneca | 18 | $370 |
| Novo Nordisk | 25 | $279 |
| Boehringer Ingelheim | 10 | $260 |
| Lilly USA, LLC | 20 | $256 |
| AbbVie(2 entities) | 19 | $212 |
| Johnson & Johnson | 11 | $181 |
| Amgen | 9 | $134 |
| Amarin Pharma, Inc. | 5 | $111 |
| Pfizer | 6 | $89 |
| Sanofi-aventis U.S. LLC | 6 | $79 |
| Merck | 4 | $64 |
| Cranial Technologies, Inc | 2 | $37 |
| Abbott | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Novartis | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Optinose US, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Organogenesis Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$107
How this compares
$3,507 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.
Other family medicine in West Point
- Michael CobbleSandy$1.3M
- Thomas ClarkProvidence$332K
- Courtney NelsonLayton$190K
- David ButtersLayton$189K
- Scott EricksonBountiful$101K
- Mark CacciamaniSalt Lake City$43K
- Clint MowerLehi$41K
- Russell AndersonTooele$30K
- Kirk OdonnellSalt Lake City$23K
- John TemplemanProvo$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.